WO2001057206A3 - Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1) - Google Patents

Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1) Download PDF

Info

Publication number
WO2001057206A3
WO2001057206A3 PCT/US2001/003504 US0103504W WO0157206A3 WO 2001057206 A3 WO2001057206 A3 WO 2001057206A3 US 0103504 W US0103504 W US 0103504W WO 0157206 A3 WO0157206 A3 WO 0157206A3
Authority
WO
WIPO (PCT)
Prior art keywords
chk
inhibition
reagent
enzyme
checkpoint kinase
Prior art date
Application number
PCT/US2001/003504
Other languages
English (en)
Other versions
WO2001057206A2 (fr
Inventor
Thale Jarvis
James Mcswiggen
Robert N Booher
Patricia S Holman
Ali R Fattaey
Original Assignee
Ribozyme Pharm Inc
Onyx Pharmaceuticals
Warner Lambert Co
Thale Jarvis
James Mcswiggen
Robert N Booher
Patricia S Holman
Ali R Fattaey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc, Onyx Pharmaceuticals, Warner Lambert Co, Thale Jarvis, James Mcswiggen, Robert N Booher, Patricia S Holman, Ali R Fattaey filed Critical Ribozyme Pharm Inc
Priority to AU39740/01A priority Critical patent/AU3974001A/en
Publication of WO2001057206A2 publication Critical patent/WO2001057206A2/fr
Publication of WO2001057206A3 publication Critical patent/WO2001057206A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des molécules d'acide nucléique, notamment des molécules d'acide nucléique antisens et enzymatiques, telles que les ribozymes en tête de marteau, les enzymes d'ADN et les antisens qui modulent l'expression du gène Chk-1.
PCT/US2001/003504 2000-02-03 2001-02-02 Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1) WO2001057206A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39740/01A AU3974001A (en) 2000-02-03 2001-02-02 Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17998300P 2000-02-03 2000-02-03
US60/179,983 2000-02-03

Publications (2)

Publication Number Publication Date
WO2001057206A2 WO2001057206A2 (fr) 2001-08-09
WO2001057206A3 true WO2001057206A3 (fr) 2002-08-29

Family

ID=22658806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003504 WO2001057206A2 (fr) 2000-02-03 2001-02-02 Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)

Country Status (2)

Country Link
AU (1) AU3974001A (fr)
WO (1) WO2001057206A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (fr) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
WO2002038143A2 (fr) * 2000-11-07 2002-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Amelioration de l'efficacite et de la securite d'une therapie genotoxique par modulation de la proteine kinase mapk p38
AU2003213057A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incoporated Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
US8232383B2 (en) * 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1495120B1 (fr) 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Moyens et procedes pour la modulation specifique de genes cibles dans l'oeil
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004094606A2 (fr) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions et methodes d'inhibition par arnic de l'angiopoietine 1 et 2 et de leur recepteur tie2
NZ561458A (en) 2005-03-29 2011-03-31 Icos Corp Heteroaryl urea derivatives useful for inhibiting CHK1
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
GB201207056D0 (en) * 2012-04-23 2012-06-06 Ucl Business Plc Wound treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011795A1 (fr) * 1997-09-05 1999-03-11 Icos Corporation Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes
WO1999054459A2 (fr) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
WO2001016306A2 (fr) * 1999-08-27 2001-03-08 Chiron Corporation Oligonucleotides chimeres antisens et formulations de transfection cellulaire
WO2001068837A2 (fr) * 2000-03-10 2001-09-20 Abbott Laboratories Oligonucleotides antisens du gene chk1 humain et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011795A1 (fr) * 1997-09-05 1999-03-11 Icos Corporation Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes
WO1999054459A2 (fr) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
WO2001016306A2 (fr) * 1999-08-27 2001-03-08 Chiron Corporation Oligonucleotides chimeres antisens et formulations de transfection cellulaire
WO2001068837A2 (fr) * 2000-03-10 2001-09-20 Abbott Laboratories Oligonucleotides antisens du gene chk1 humain et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTMANN K-H ET AL: "NOVEL CHEMISTRY", APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, NEW YORK, WILEY-LISS, US, 1998, pages 73 - 107, XP002119324, ISBN: 0-471-17279-0 *
SHIEH SHEAU-YANN ET AL: "The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.", GENES & DEVELOPMENT., vol. 14, no. 3, 1 February 2000 (2000-02-01), pages 289 - 300, XP002188228, ISSN: 0890-9369 *
USMAN N ET AL: "CHEMICAL MODIFICATION OF HAMMERHEAD RIBOZYMES: ACTIVITY AND NUCLEASE RESISTANCE", NUCLEIC ACIDS SYMPOSIUM SERIES, no. 31, 9 November 1994 (1994-11-09), pages 163 - 164, XP002002020, ISSN: 0261-3166 *

Also Published As

Publication number Publication date
WO2001057206A2 (fr) 2001-08-09
AU3974001A (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO2001057206A3 (fr) Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)
WO2003006652A3 (fr) Inhibition d'isoformes specifiques d'histone deacetylase
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
WO2003102214A3 (fr) Procede d'interference efficace par arn dans des cellules de mammifere
AU2001276843A1 (en) Nucleic acid enzyme biosensor for ions
WO2002014472A3 (fr) Procedes ameliores d'extinction de gene utilisant des sequences repetees inversees
WO1998033893A3 (fr) Traitement par l'acide nucleique enzymatique de pathologies ou etats apparentes aux taux des recepteurs du facteur de croissance epidermique
WO2000032757A3 (fr) Enzymes biosynthetiques de la vitamine e d'origine vegetale
AU2001243259A1 (en) Genes encoding denitrification enzymes
WO2001047543A3 (fr) Activation et inhibition du systeme immunitaire
WO1999055888A3 (fr) Enzymes biosynthetiques carotenoides
WO1999049050A3 (fr) Genes d'huile de limnanthes
WO2001059103A3 (fr) Methode et reactif destines a la modulation et au diagnostic de l'expression genetique de cd20 et de nogo
WO1998032846A3 (fr) Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
WO2001088124A3 (fr) Procede et reactif destine a l'inhibition d'erg
WO1999002673A3 (fr) Sequences oligonucleotidiques antisens servant d'inhibiteurs de micro-organismes
WO2003057843A3 (fr) Procedes et materiaux de modulation de trpc4
Cannistraro et al. The 5′ ends of RNA oligonucleotides in Escherichia coli and mRNA degradation
AU2003213057A1 (en) Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
AU4934099A (en) Method for enzymatic amplification of nucleic acid
WO2003034985A3 (fr) Interference par telomerase
AU1721600A (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2001007579A3 (fr) Procedes et compositions conçus pour determiner une activite enzymatique
WO2002091926A3 (fr) Inhibiteurs des isoformes de méthyltransférase d'adn
WO2002011674A3 (fr) Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 39740/01

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP